FIXX News and Press, Homology Medicines Inc. From 09/03/19

BEDFORD, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in two upcoming investor conferences. Citi’s 14 th Annual Biotech Conference Four Seasons Hotel, Bos...

Homology Medicines (NASDAQ: FIXX ): Q2 GAAP EPS of -$0.61 misses by $0.06 . More news on: Homology Medicines, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Phase 1/2 pheNIX Study of HMI-102 Gene Therapy Candidate for Adults with PKU Continues, Additional Sites Enrolling and Initial Data Expected by Year End -             - Fast Track Designation Granted in the U.S. for HMI-102, A...

BEDFORD, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in a fireside chat at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, at 11:30 a.m. ET...

Homology Medicines ( FIXX -20% ) slumps on a 6x surge in volume in apparent response to an abstract published on July 21 by bioRxiv (pronounced "bio-archive"). More news on: Homology Medicines, Inc., Healthcare stocks news, Stocks on the move, Read more ...

- Celgene Executive with Early- and Late-Stage Global Clinical Development Experience Joins as Homology Advances Lead Gene Therapy Program for PKU Through the Clinic - BEDFORD, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines compan...

- Sam Rasty, Ph.D., Departs as Chief Operating Officer to Lead an Emerging Biotech - BEDFORD, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today changes to its leadership team, which positions the Company for...

- Phase 1/2 pheNIX Study of Gene Therapy Candidate HMI-102 is Underway and Initial Clinical Data is Anticipated by Year End - BEDFORD, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of dat...

BEDFORD, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, at 8:30 a.m. ET at The ...

- Enrollment in the pheNIX Study Marks First Gene Therapy Clinical Trial for PKU - BEDFORD, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has commenced enrollment of the Phase 1/2 pheNIX trial for...